<DOC>
	<DOCNO>NCT01586494</DOCNO>
	<brief_summary>The purpose study compare pharmacokinetics ( PK ) single oral dos ULTRAM Extended Release ( ER ) 2 dose level child 7 11 year old , inclusive ( 11 year 364 day ) pain due injury nonmalignant disease , PK adult , respect PK parameter AUCâˆž ( area curve ) racemic tramadol . PK explore drug absorb body , distribute within body , remove body time .</brief_summary>
	<brief_title>A Pharmacokinetic , Tolerability , Safety Study ULTRAM ER Children With Pain</brief_title>
	<detailed_description>This multicenter , open-label ( people know identity intervention ) , 2-group , single dose study . Within group participant Parts 1 2 , least 1/3 participant female , least 1/3 participant male , least 1/3 participant age 8 year , least 1/3 participant age 10 year . Participants assign 1 group . Each group participant receive single oral dose ULTRAM ER 1 occasion . Group 1 receive dose ULTRAM ER close 2 mg/kg , base participant 's body weight adjust dose 25 mg increment . Following completion evaluation Group 1 , pharmacokinetic data evaluate target dose Group 2 achieve level exposure similar see single 200 mg ULTRAM ER dose adult . The maximum dose ULTRAM ER exceed 6 mg/kg 300 mg . When study physician , investigator , medical monitor agree PK drug well-characterized drug well tolerate , enrollment begin Group 2 study . The sponsor 's responsible Medical Officer evaluate safety calculate dose Group 2 participant evaluation adverse drug event pay particular attention event suggestive either opioid toxicity serotonin toxicity .</detailed_description>
	<mesh_term>Tramadol</mesh_term>
	<criteria>Confirmed need control pain due injury nonmalignant disease influence fluid shift general drug disposition Weighs least 20 kg Female participant must premenarchal opinion investigator sexually active Able swallow intact tablet aid water ( participant may chew , divide , dissolve , crush study drug ) Signed informed consent document indicate he/she understands purpose procedure require study willing participate study Informed consent sign parent ( ) legal guardian ( ) participant History current clinically significant medical illness condition include ( limited ) cardiac disease , hematologic disease , coagulation disorder , lipid abnormality , significant pulmonary disease , diabetes mellitus , renal hepatic insufficiency , thyroid disease , neurologic psychiatric disease , infection , illness condition investigator considers exclude participant could interfere interpretation study result</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Pain</keyword>
	<keyword>ULTRAM ER</keyword>
	<keyword>Tramadol hydrochloride</keyword>
	<keyword>Children</keyword>
</DOC>